Core Viewpoint - Silo Pharma has filed a provisional patent application for its lead asset SPC-15, which shows enhanced efficacy in treating stress-induced psychiatric disorders, particularly PTSD and anxiety [1][6]. Company Overview - Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases [7]. Patent and Technology - The provisional patent covers a dual-action method and composition aimed at combating stress-induced pathophysiology and reducing various stress-induced psychiatric behaviors [3]. - Silo currently holds issued patents and has several expanded patent applications pending for SPC-15, which was licensed through a collaboration with Columbia University [2][4]. - A separate expanded provisional patent application has been filed to target NMDARs and 5-HT4Rs for extended behavioral effects against stress-induced behaviors [5]. Research and Development - SPC-15 is an intranasal serotonin 5-HT4 receptor agonist that has shown significant improvement in behavioral outcomes in preclinical studies [3][6]. - The company is collaborating with Columbia University for preclinical studies and has exclusive global rights for the development and commercialization of SPC-15 [6]. Future Prospects - The potential eligibility of SPC-15 for the FDA's streamlined 505(b)(2) regulatory pathway may accelerate its approval process [6].
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment